Klotho inhibits growth and promotes apoptosis in human lung cancer cell line A549 by Chen, Bo et al.
Chen et al. Journal of Experimental & Clinical Cancer Research 2010, 29:99
http://www.jeccr.com/content/29/1/99
Open Access RESEARCH
© 2010 Chen et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Research Klotho inhibits growth and promotes apoptosis in 
human lung cancer cell line A549
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Abstract
Background: Klotho, as a new anti-aging gene, can shed into circulation and act as a multi-functional humoral factor 
that influences multiple biological processes. Recently, published studies suggest that klotho can also serve as a 
potential tumor suppressor. The aim of this study is to investigate the effects and possible mechanisms of action of 
klotho in human lung cancer cell line A549.
Methods: In this study, plasmids encoding klotho or klotho specific shRNAs were constructed to overexpress or 
knockdown klotho in vitro. A549 cells were respectively treated with pCMV6-MYC-KL or klotho specific shRNAs. The 
MTT assay was used to evaluate the cytotoxic effects of klotho and flow cytometry was utilized to observe and detect 
the apoptosis of A549 cells induced by klotho. The activation of IGF-1/insulin signal pathways in A549 cells treated by 
pCMV6-MYC-KL or shRNAs were evaluated by western blotting. The expression levels of bcl-2 and bax transcripts were 
evaluated by quantitative reverse transcription-polymerase chain reaction (qRT-PCR).
Results: Overexpression of klotho reduced the proliferation of lung cancer A549 cells, whereas klotho silencing in A549 
cells enhanced proliferation. Klotho did not show any effects on HEK-293 cells. Klotho overexpression in A549 cells was 
associated with reduced IGF-1/insulin-induced phosphorylation of IGF-1R (IGF-1 receptor)/IR (insulin receptor) (P < 
0.01). Overexpression of klotho can promote the apoptosis of A549 cells (P < 0.01). Overexpression of klotho, a bcl 
family gene bax, was found up-regulated and bcl-2, an anti-apoptosis gene, was found down-regulated (P < 0.01). In 
contrast, bax and bcl-2 were found down-regulated (P < 0.05) and up-regulated (P < 0.01), respectively when silencing 
klotho using shRNAs.
Conclusions: Klotho can inhibit proliferation and increase apoptosis of A549 cells, this may be partly due to the 
inhibition of IGF-1/insulin pathways and involving regulating the expression of the apoptosis-related genes bax/bcl-2. 
Thus, klotho can serve as a potential tumor suppressor in A549 cells.
Background
Aging is the greatest risk factor for cancer. About 77% of
all cancers are diagnosed in people over 55 years old, with
men facing a 50% chance of developing cancer, whereas
women having a 35% chance. Thus, with the aging popu-
lation increasing, it is expected that cancer will become
an enormous challenge. Lung cancer is the leading cause
of cancer deaths worldwide because of its high incidence
and mortality, with 5-year survival rates approximately
10% for non-small cell lung cancer (NSCLC) [1]. It is
urgent to investigate the mechanism of tumorigenesis to
improve survival rate.
Recently, klotho, a new anti-aging gene, has gained
great attention. The klotho gene plays a critical role in
regulating aging and the development of age-related dis-
eases in mammals: Loss of klotho can result in multiple
aging-like phenotypes [2], while overexpression of klotho
gene extends lifespan by 20-30% [3]. The klotho gene is
composed of 5 exons [4,5] and encodes a type-I single-
pass transmembrane protein (1014-amino acid-long).
The intracellular domain is short (10-amino acid-long)
and no known functional domains exist. The extracellular
domain is composed of two domains, termed KL1 and
KL2, with weak homology. Each domain has homology to
family 1 glycosidases, including lactose-phlorizin hydro-
lase of mammals and β-glucosidases of bacteria and
plants [2,6]. These enzymes have exoglycosidase activity
that hydrolyzes β-glucosidic linkage in saccharides, glyco-
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proteins, and glycolipids. However, recombinant klotho
protein did not have β-glucosidase-like enzymatic activ-
ity, probably due to critical amino acid residues in puta-
tive active centers of klotho protein diverge from those
conserved throughout the β-glucosidase family of
enzymes [2,6].
Klotho can involve in multiple biological processes, and
the precise mechanism was widely and deeply investi-
gated [7]. It is now widely accepted that klotho inhibits
insulin and insulin-like growth factor 1 (IGF-1) signaling
pathways [3,8]. Moderate inhibition of the insulin/IGF-1
signaling pathways has been viewed as one of the evolu-
tionarily conserved mechanisms for suppressing aging
[9]. In addition, klotho functions as a co-receptor for
fibroblast growth factor 23 (FGF23), which down-regu-
lates the expression of 1,25-dihydroxyvitamin D3 and
phosphate reabsorption [10,11]. Klotho can also increase
the resistance to oxidative stress [12]. Furthermore,
klotho may protect the cardiovascular system by increas-
ing nitric oxide (NO) production [13].
Multiple lines of evidence suggest the involvement of
the IGF-1/insulin pathways across a range of malignan-
cies, including both NSCLC and small cell lung cancer
(SCLC) [14-17], and inhibition of IGF-1 signaling path-
way is a potential therapy for human lung cancer [18].
Intriguingly, a recently published research suggests that
klotho serves as a potential tumor suppressor and iden-
tify it as an inhibitor of the IGF-1 pathway and activator
of the FGF pathway in human breast cancer [19]. In this
study, we detected changes in biological behavior after
overexpression or knockdown of klotho in lung cancer
cell line A549, and found that it also acts as a potential
tumor suppressor in lung cancer.
Materials and methods
Constructs
The MYC-tagged klotho expression vector (pCMV6-
MYC-KL) and its entry vector (pCMV6) were designed
and purchased from OriGene (Rockville, MD, USA).
Klotho-directed stealth shRNA duplex oligoribonucle-
otides and control shRNAc were also designed and pur-
chased from OriGene (Rockville, MD, USA). And their
sequences are as follows:
sh-1: CCTAAGCTCTCACTGGATCAATCCTCGAA;
sh-2: CTGAGGCAACTGCTTTCCTGGATTGACCT;
sh-3: GGTCACTCACTACCGCTTCTCCATCTCGT;
sh-4: GTTACAGCATCAGGCGTGGACTCTTCTAT;
shRNAc, scrambled: Non-effective 29-mer scrambled
shRNA cassette in pRS plasmid
Cells culture and transfections
The NSCLC A549 and the noncancerous human embry-
onic kidney (HEK) 293 cell lines were purchased from
ATCC (Manassas, VA, USA), and were maintained in
Dulbecco's Modified Eagle's Medium (DMEM) contain-
i n g  1 0 %  f e t a l  b o v i n e  s e r u m  ( F B S ) ,  a n d  c u l t u r e d  i n  a
humidified atmosphere of 95% air and 5% CO2 at 37°C.
All transfections used LipofectAMINE 2000 (Invitrogen,
CA, USA). Stable clones were generated by selection in
complete culture medium containing 700 μg/ml G418.
RNA extraction and quantitative real-time RT-PCR
Total RNA was extracted from cells with Trizol reagent
(Invitrogen, CA, USA) according to the manufacturer's
instructions. Gene expressions were detected by quanti-
tative real-time RT-PCR (qRT-PCR) using the standard
SYBR Green RT-PCR kit (Takara, Dalian, China) accord-
ing to the manufacture's instructions. Briefly, the cDNA
was synthesized using the RevertAid First-Strand cDNA
Synthesis kit (Fermentas, Vilnius, Lithuania) according to
the manufacturer's protocol. The specific primer pairs
and the amplified products are as follows: klotho (104 bp),
sense: 5'-GCTCTCAAAGCCCACATACTG -3'; anti-
sense: 5'-GCAGCATAACGATAGAGGCC -3'; bcl-2 (182
bp), sense: 5'-GTGTGGAGAGCGTCAACC -3'; anti-
sense: 5'-CTTCAGAGACAGCCAGGAG -3'; bax  (91
bp), sense: 5'-ATGCGTCCACCAAGAAGC- 3'; anti-
sense: 5'-ACGGCGGCAATCATCCTC -3'; β-actin (205
bp) as an internal, primers, sense: 5'-TGACGTGGA-
CATCCGCAAAG -3'; antisense: 5'-CTGGAAGGTGGA-
CAGCGAGG -3'. The relative levels of gene mRNA
transcripts were normalized to the control β-actin. Rela-
tive gene expression was quantified using the GraphPad
Prism 4.0 software (GraphPad Software, San Diego, CA,
USA). PCR consisted of initial denaturation at 94°C for 5
min, followed by 30 reaction cycles (30 seconds at 94°C,
30 seconds at 60°C, and 30 seconds at 72°C) and a final
cycle at 72°C for 10 min.
Western blot analysis
The cells were lysed in 0.1 ml lysis buffer (0.1% SDS, 1%
NP-40, 50 mM HEPES, pH 7.4, 2 mM EDTA, 100 mM
NaCl, 5 mM sodium orthovanadate, and 1% protease
inhibitor mixture set I; Calbiochem) on ice for 30 min,
and lysates were cleared by centrifugation at 12,000 rpm
for 15 min. Proteins were separated in 10% SDS-PAGE
and electroblotted onto polyvinylidene difluoride mem-
brane, blocked for 1.5 hr at room temperature in 5% non-
fat milk or 1% BSA, and probed with anti-IGF-1β recep-
tor (111A9) and phospho-IGF-1R (Y1135/1136), phos-
pho-IR (Y1150/1151), and anti-β-actin (Cell Signaling
Technology, MA, USA) antibody. Following incubation
with the corresponding peroxidase-conjugated secondary
antibodies, Chemiluminent detection was performed
with the ECL kit (Pierce, Rockford, IL, USA).
MTT viability assay
Cell proliferation was evaluated by a modified 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay. The test cells in exponential growth wereChen et al. Journal of Experimental & Clinical Cancer Research 2010, 29:99
http://www.jeccr.com/content/29/1/99
Page 3 of 7
plated at a final concentration of 8 × 103 cells/well in 96-
well culture plates for different culture time. MTT (20 μl,
10 mg/ml) was then added. After an additional 4 hr of
incubation, the reaction was terminated by removal of
the supernatant and addition of 150 μl DMSO for 10 min.
Optical density (OD) of each well was measured at 570
nm using ELISA reader (ELx808 Bio-Tek Instruments,
Winooski, USA).
Detection of apoptosis by flow cytometry
Cells were stained with fluorescein isothiocyanate (FITC)
labeled annexin-V, and simultaneously with propidium
iodide (PI) stain, to discriminate intact cells (annexin-/PI-
) from apoptotic cells (annexin+/PI-), and necrotic cells
(annexin+/PI+). A total of 1.0 × 106 cells were washed
twice with ice-cold PBS and incubated for 30 min in a
binding buffer (1 μg/ml PI and 1 μg/ml FITC labeled
annexin-V), respectively. FACS analysis for annexin-V
and PI staining was performed by flow cytometer
(Coulter, Beckman, CA, USA). All experiments were per-
formed in triplicate.
Statistical analysis
Data were expressed as mean ± SD. Statistical analysis
was performed using SPSS software (Release 13.0, SPSS
Inc.). The difference between two groups was analyzed by
the Student's t-test. A value of p < 0.05 was considered as
statistical significance.
Results
Klotho expression after transfection with pCMV6-MYC-KL 
or shRNA
To determine the effects of overexpression or knockdown
of klotho in A549 and HEK-293 cells, we generated a
MYC-tagged klotho expressison vector (pCMV6-MYC-
KL), four klotho directed-shRNAs and a negative control-
shRNA (shRNAc). After the cells were transfected with
pCMV6-MYC-KL or klotho specific-shRNAs, the mRNA
levels of klotho were analyzed with qRT-PCR. Obviously,
the levels of klotho mRNA transcripts were highly ele-
vated in pCMV6-MYC-KL-transfected cells when com-
pared with pCMV6 (Figure 1A, whereas in klotho
direced-shRNA cells significantly decreased by ~ 89%
compared with shRNAc (P < 0.01). The results indicate
that all four shRNAs are working well, and the effects of
sh-2 and sh-4 are very similar and more robust than the
other two shRNAs (Figure 1B). Thus, our klotho expres-
sion plasmid and klotho-specific shRNAs worked effi-
ciently.
Klotho inhibits lung cancer cell growth and may involve in 
IGF-1-induced A549 proliferation
A549 and HEK-293 cells were transfected with either
pCMV6-MYC-KL vector or empty vector (pCMV6). To
assess the effects of klotho expression, A549 clones,
which expressed either pCMV6 or pCMV6-MYC-KL,
were generated. The proliferation of klotho-expressing
cells, as evaluated by MTT assay, was significantly inhib-
ited when compared with the controls. The inhibition
rates ranged from 7% to 20%, and the results are shown in
Figure 2A (P < 0.05). However, we did not find any signif-
icance in HEK-293 cells after overexpression of klotho (P
> 0.05; Figure 2B).
As we found some klotho expression in A549 cells, we
examined the effects of downregulation of klotho in these
c e l l s .  F o u r  k l o t h o - s p e c i f i c  s h R N A s  w e r e  d e s i g n e d  a n d
tested for their ability to silence klotho expression in
A549 cells, compared with negative control group
shRNAc. We investigated the growth condition after
transfection with the sh-2 and sh-4, respectively. Follow-
ing downregulation of klotho, proliferation of A549 cells,
Figure 1 Relative klotho gene transcripts by qRT-PCR. (A) A549 
and HEK-293 cells transfected with either MYC-tagged klotho expressi-
son vector (MYC-KL) or an entry vector (pCMV6). (B) A549 cells trans-
fected with four klotho directed-shRNAs and a negative control-shRNA 
(shRNAc). Data shown are the mean results ± SD of a representative ex-
periment performed in triplicate (n = 3), *indicates p < 0.01. Statistical 
comparisons showed that our klotho expression plasmid and klotho-
specific shRNA could work efficiently.
Figure 2 Effects of klotho on A549 and HEK-293 cells growth dy-
namics determined by MTT. (A) and (B) are A549 and HEK-293 cells 
transfected either with pCMV6 or with MYC-KL, respectively.Chen et al. Journal of Experimental & Clinical Cancer Research 2010, 29:99
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as assessed by MTT assay, elevated by 11% to 28% and
13% to 25% using sh-2 and sh-4, compared with shRNAc,
respectively (Figure 3A).
It is widely accepted that klotho inhibits the activation
of the IGF-1 pathway [3,8], which has an important func-
tion in lung cancer tumorigenesis, and IGF-1 induces
A549 cells proliferation [20]. To test the ability of klotho
to modulate IGF-1-induced proliferation and survival,
A549 cells were transiently transfected with either
pCMV6 or pCMV6-MYC-KL and grown in 0.5% serum
with either IGF-1 or a control vehicle for 24-96 hr. Klotho
transfection obviously inhibited cell proliferation in the
untreated cells, and this inhibition was only mildly
restored following addition of IGF-1 to the cells. Thus,
whereas IGF-1 increased cell proliferation by up to 33% in
control pCMV6-transfected cells, cell proliferation in the
pCMV6-MYC-KL-transfected cells increased by only
11% (Figure 3B).
Klotho inhibits the activation of the IGF-1/insulin pathways 
and is directly associated with IGF-1R in lung cancer cells
We studied the effect of klotho on IGF-1 pathway activa-
tion in A549 lung cancer cells, which express high levels
of IGF-1R and show an enhanced proliferation following
IGF-1 treatment. A549 cells were transfected with either
pCMV6-MYC-KL or pCMV6, starved for 24 hr, treated
with IGF-1 (10 min, 25 nM) and analysed using western
blotting for the expression and phosphorylation of IGF-
1R. Klotho overexpression in A549 cells was associated
with reduced phosphorylation of IGF-1R (P < 0.01). The
effects of overexpression of klotho on the insulin (10 min,
100 nM) pathway were also examined, and similar to
IGF-1 activation, klotho overexpression in A549 cells was
associated with reduced phosphorylation of insulin
receptor (IR, P < 0.01), indicating that klotho also inhib-
ited the activation of the insulin pathway in A549 cells.
We further studied the effect of klotho knockdown in
A549 cells using sh-2, and found a significant increase in
IGF-1R/IR phosphorylation following IGF-1/insulin
stimulation in sh-2-transfected cells compared with siR-
NAc-transfected cells. The results were shown in Figure 4.
Klotho-induced apoptosis of A549 cells
To determine the effects of overexpression or downregu-
lation of klotho on the klotho-induced apoptosis in A549
cells, the rate of apoptosis was evaluated by flow cytome-
try analysis. As shown in Figure 5, the effects of klotho-
induced apoptosis were investigated in pCMV6 cells as
well as cells transfected with pCMV6-MYC-KL, sh-2 or
shRNAc. We found that the significantly elevated per-
centage of apoptosis in the cells transfected with klotho
compared with the control cells (P < 0.01), while there
was no significant difference between sh-2-transfected
and shRNAc-transfected cells (P > 0.05).
Apoptosis-related gene expression in the klotho-induced 
apoptosis
We next investigated potential pathways involved in
klotho-induced apoptosis. As shown in Figure 6, overex-
pression of klotho, a bcl family gene bax, was found up-
regulated compared with pCMV6-transfected cells while
down-regulated when transfected with klotho specific-
shRNA sh-2 compared with shRNAc-transfected cells. In
contrast, bcl-2, an anti-apoptosis gene, was found down-
regulated when overexpression of klotho, while up-regu-
lated when downregulation of klotho using sh-2. Similar
results were obtained when comparing sh-4 group with
shRNAc group. These results showed that bax and bcl-2-
Figure 3 Effects of klotho on A549 cells growth dynamics deter-
mined by MTT. (A) A549 cells transfected by negative control-shRNA 
(shRNAc) or klotho-directed shRNAs sh-2 and sh-4. (B) A549 cells were 
transfected with either MYC-KL or pCMV6, starved for 24 hr and treated 
by IGF-1 (25 nM) for 24-96 hr.
Figure 4 Downregulation of the IGF-1/insulin pathways by 
klotho in lung cancer cell line A549. A549 cells were transfected 
with either MYC-KL or control vector pCMV6. After 24 hr, cells were se-
rum-starved for 24 hr and treated with IGF-1 (10 min, 25 nM) or insulin 
(10 min, 100 nM). Following treatment, cells were harvested and pro-
teins were resolved and immunoblotted using antibodies either di-
rected against phospho (P) and total (T) IGF-1R or phospho (P) and 
total (T) insulin-R (IR). Similar treatment was done when silenced the 
klotho of the cells using sh-2 or control shRNAc. Data shown are the 
mean results ± SD of a representative experiment performed in tripli-
cate (n = 3), *indicates p < 0.01.
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related apoptosis pathways may involve in the klotho-
induced apoptosis.
Discussion
Recent studies demonstrated that mutation of a single
gene in chromosome 13, which is now widely identified
as klotho, causes extensive aging phenotypes including
arteriosclerosis, vascular calcifications, soft tissue calcifi-
cations, emphysema, hypoactivity, gonadal dysplasia,
infertility, skin atrophy, ataxia, hypoglycemia and severe
hyperphosphatemia. It may be associated with increased
concentrations of 1,25(OH)2D3, an essential vitamin for
calcium metabolism [2]. Thus, klotho is widely recog-
nized as an anti-aging gene. In addition to its role in
aging, recent research found that it can involve in multi-
ple cell signal pathways with complex roles. In addition to
regulating insulin and IGF-1, acting as a co-receptor for
FGF23 and resisting to oxidative stress, it also influences
several intracellular signaling pathways which underlie
the molecular mechanism of klotho function, such as
p53/p21 [21], cAMP [22], PKC and Wnt [10] signaling
pathways.
Ample clinical and laboratory data indicate a critical
role for insulin/IGF-1 signaling in lung cancer. Notably,
intracellular presence of insulin is associated with adverse
prognosis in human lung adenocarcinoma [17]; High cir-
culating IGF-1 levels are associated with increased risk of
lung cancer [16], and inhibition of insulin/IGF-1 signaling
inhibits growth of lung cancer cells [20]. Since secreted
klotho protein can inhibit the activation of insulin/IGF-1
receptors, we presumed that klotho may also function as
a suppressor of lung cancer. In this study, we investigated
the effects of klotho in lung cancer cells. We found that
the expression of klotho in lung cancer cell line A549 is
low, and klotho overexpression inhibits, whereas klotho
downregulation enhances, lung cancer cell growth. In
addition, we found that overexpression of klotho was
associated with reduced phosphorylation of IGF-1R using
IGF-1 stimulation, and similar results were found in the
evaluation of insulin pathway. Our results consistent with
recently published paper which demonstrated that klotho
can act as a tumor suppressor and a modulator of the
IGF-1 and FGF pathways in human breast cancer [19].
The possible reason may be that IGF-1 pathway involves
in tumorigenesis of this two cancer types. In sum, our
results indicate that klotho inhibit A549 cells growth
partly due to inhibition of IGF-1/insulin pathways.
The regulation of apoptosis is a complex process and
involves a number of gene products including bcl-2 pro-
tein family and cell cycle-regulatory proteins. The bcl-2
family of proteins, as important regulators in both the
inhibition and the promotion of apoptosis, forms ion
Figure 5 Induction of A549 cells apoptosis after overexpression 
of klotho. (A) Figures of apoptosis by flow cytometry. a, b, c, d, e and f 
indicate control, mock, pCMV6, MYC-KL, shRNAc and sh-2 groups, re-
spectively. (B) The data present the average number of apoptotic cells 
(± SD) in three independent experiments. pCMV6 vs MYC-KL, * indi-
cates p < 0.01.
A
B
Figure 6 Influence of down-stream genes expression in klotho-
induced apoptosis. (A) After tansfected with MYC-KL, bax and bcl-2 
genes transcripts were found up-regulated and down-regulated, re-
spectively. (B) Compared with shRNAc group, bax and bcl-2 genes 
transcripts were found down-regulated and up-regulated respectively 
in sh-2/4-transfected group. Data shown are the mean results ± SD of 
a representative experiment performed in triplicate (n = 3), *indicates 
p < 0.05; **indicates p < 0.01.Chen et al. Journal of Experimental & Clinical Cancer Research 2010, 29:99
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channels in biological membranes, and this ion channel
regulates apoptosis by influencing the permeability of the
intracellular membrane of mitochondria [23,24]. It was
proposed that the ratio between bcl-2 and bax is more
important in the regulation of apoptosis than the level of
each bcl-2 family protein alone [25]. Our data indicated
that treatment with klotho markedly decreased the
mRNA levels of bcl-2 and increased bax expression, while
the opposite results were obtained when silencing klotho.
Thus, the bax/bcl-2 ratio increased with the treatment of
klotho. Intriguingly, though the apoptosis-related genes
transcripts were all statistically significant between
experimental groups and their controls, our flow cytome-
try results did not show any significance between klotho-
specific shRNA groups and shRNAc groups. The possible
reason may be gene transcripts are more sensitive and
more easily to be detected than the changes in protein
and function levels. The apoptosis of A549 cells with low
klotho expression may be too weak to observe after
knockdown of klotho. In contrast, after forced expression
of klotho, the expression of klotho increased several
thousand times. Thus, klotho can show effects more
obviously, and the apoptosis of A549 cells were more eas-
ily to be detected. Moreover, besides bax/bcl-2 signals,
there are other mechanisms may take part in klotho-
induced A549 cells apoptosis. In addition, forced expres-
sion of any protein can cause endoplasmic reticulum (ER)
stress, which potentially results in slow proliferation, cell
cycle arrest, and/or apoptosis [26]. But, our klotho silenc-
ing results may eliminate this possibility. Though having
no statistically significant change, the apoptosis of A549
cells tend to decrease after knockdown of klotho. And the
changes of apoptosis-related genes bax/bcl-2 also sup-
ported that klotho may promote apoptosis of A549 cells.
All these results suggested that the expression levels of
anti-apoptotic bcl-2 decreased and pro-apoptotic bax
increased, which might play a key role in klotho-induced
apoptosis in the A549 cells.
Conclusions
In summary, klotho, a potential tumor suppressor, can
inhibit the growth of lung cancer cells A549 and promote
their apoptosis, this may be partly due to the inhibition of
IGF-1/insulin pathways and involving regulating the
expression of the apoptosis-related genes bax/bcl-2. The
function of klotho is very complex, and the signal path-
ways in cancer development are interwound and cross-
linking, so the exact role and working mechanisms of
klotho in vitro and in vivo are still waiting to be explored.
Further study of the biological functions of klotho may be
helpful in developing new strategies in lung cancer treat-
ment.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
In our study, all authors are in agreement with the content of the manuscript.
Each author's contribution to the paper: BC: First author, Participated in
research design, the writing of the paper, the performance of the research and
data analysis. JQW: Corresponding author, research instruction, data analysis,
development of final manuscript. XLW: the performance of the research and
data analysis. WHZ: research instruction, development of final manuscript.
Acknowledgements
This work was partly supported by the grants from the National Natural Sci-
ence Foundation of China (No. 30971320), Foundation of Jiangsu Key 
Researchers in Medical Science (RC2007051), and Foundation of Jiangsu 
Health Department in Scientific Research (P200904).
Author Details
Department of Geriatrics, The First Affiliated Hospital of Nanjing Medical 
University, Nanjing 210029, Jiangsu, China
References
1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics.  CA 
Cancer J Clin 2009, 59:225-249.
2. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, 
Ohyama Y, Kurabayashi M, Kaname T, Kume E, et al.: Mutation of the 
mouse klotho gene leads to a syndrome resembling ageing.  Nature 
1997, 390:45-51.
3. Kurosu H, Yamamoto M, Clark JD, Pastor JV, Nandi A, Gurnani P, 
McGuinness OP, Chikuda H, Yamaguchi M, Kawaguchi H, et al.: 
Suppression of aging in mice by the hormone Klotho.  Science 2005, 
309:1829-1833.
4. Matsumura Y, Aizawa H, Shiraki-Iida T, Nagai R, Kuro-o M, Nabeshima Y: 
Identification of the human klotho gene and its two transcripts 
encoding membrane and secreted klotho protein.  Biochem Biophys Res 
Commun 1998, 242:626-630.
5. Shiraki-Iida T, Aizawa H, Matsumura Y, Sekine S, Iida A, Anazawa H, Nagai 
R, Kuro-o M, Nabeshima Y: Structure of the mouse klotho gene and its 
two transcripts encoding membrane and secreted protein.  FEBS Lett 
1998, 424:6-10.
6. Mian IS: Sequence, structural, functional, and phylogenetic analyses of 
three glycosidase families.  Blood Cells Mol Dis 1998, 24:83-100.
7. Imura A, Iwano A, Tohyama O, Tsuji Y, Nozaki K, Hashimoto N, Fujimori T, 
Nabeshima Y: Secreted Klotho protein in sera and CSF: implication for 
post-translational cleavage in release of Klotho protein from cell 
membrane.  FEBS Lett 2004, 565:143-147.
8. Utsugi T, Ohno T, Ohyama Y, Uchiyama T, Saito Y, Matsumura Y, Aizawa H, 
Itoh H, Kurabayashi M, Kawazu S, et al.: Decreased insulin production and 
increased insulin sensitivity in the klotho mutant mouse, a novel 
animal model for human aging.  Metabolism 2000, 49:1118-1123.
9. Tatar M, Bartke A, Antebi A: The endocrine regulation of aging by 
insulin-like signals.  Science 2003, 299:1346-1351.
10. Liu H, Fergusson MM, Castilho RM, Liu J, Cao L, Chen J, Malide D, Rovira II, 
Schimel D, Kuo CJ, et al.: Augmented Wnt signaling in a mammalian 
model of accelerated aging.  Science 2007, 317:803-806.
11. Liu S, Gupta A, Quarles LD: Emerging role of fibroblast growth factor 23 
in a bone-kidney axis regulating systemic phosphate homeostasis and 
extracellular matrix mineralization.  Curr Opin Nephrol Hypertens 2007, 
16:329-335.
12. Mitani H, Ishizaka N, Aizawa T, Ohno M, Usui S, Suzuki T, Amaki T, Mori I, 
Nakamura Y, Sato M, et al.: In vivo klotho gene transfer ameliorates 
angiotensin II-induced renal damage.  Hypertension 2002, 39:838-843.
13. Saito Y, Nakamura T, Ohyama Y, Suzuki T, Iida A, Shiraki-Iida T, Kuro-o M, 
Nabeshima Y, Kurabayashi M, Nagai R: In vivo klotho gene delivery 
protects against endothelial dysfunction in multiple risk factor 
syndrome.  Biochem Biophys Res Commun 2000, 276:767-772.
Received: 15 June 2010 Accepted: 19 July 2010 
Published: 19 July 2010
This article is available from: http://www.jeccr.com/content/29/1/99 © 2010 Chen et al; licensee BioMed Central Ltd.  This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Journal of Experimental & Clinical Cancer Research 2010, 29:99Chen et al. Journal of Experimental & Clinical Cancer Research 2010, 29:99
http://www.jeccr.com/content/29/1/99
Page 7 of 7
14. Hofmann F, García-Echeverría C: Blocking the insulin-like growth factor-I 
receptor as a strategy for targeting cancer.  Drug Discov Today 2005, 
10:1041-1047.
15. Tao Y, Pinzi V, Bourhis J, Deutsch E: Mechanisms of disease: signaling of 
the insulin-like growth factor 1 receptor pathway-therapeutic 
perspectives in cancer.  Nat Clin Pract Oncol 2007, 4:591-602.
16. Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X: Plasma levels of insulin-like 
growth factor-I and lung cancer risk: a case-control analysis.  J Natl 
Cancer Inst 1999, 91:151-156.
17. Mattarocci S, Abbruzzese C, Mileo AM, Visca P, Antoniani B, Alessandrini G, 
Facciolo F, Felsani A, Radulescu RT, Paggi MG: Intracellular presence of 
insulin and its phosphorylated receptor in non-small cell lung cancer.  
J Cell Physiol 2009, 221:766-770.
18. Ma Z, Dong A, Kong M, Qian J: Silencing of the type 1 insulin-like growth 
factor receptor increases the sensitivity to apoptosis and inhibits 
invasion in human lung adenocarcinoma A549 cells.  Cell Mol Biol Lett 
2007, 12:556-572.
19. Wolf I, Levanon-Cohen S, Bose S, Ligumsky H, Sredni B, Kanety H, Kuro-o 
M, Karlan B, Kaufman B, Koeffler HP, Rubinek T: Klotho: a tumor 
suppressor and a modulator of the IGF-1 and FGF pathways in human 
breast cancer.  Oncogene 2008, 27:7094-7105.
20. Dong AQ, Kong MJ, Ma ZY, Qian JF, Xu XH: Down-regulation of IGF-IR 
using small, interfering, hairpin RNA (siRNA) inhibits growth of human 
lung cancer cell line A549 in vitro and in nude mice.  Cell Biol Int 2007, 
31:500-507.
21. de Oliveira RM: Klotho RNAi induces premature senescence of human 
cells via a p53/p21 dependent pathway.  FEBS Lett 2006, 580:5753-5758.
22. Yang J, Matsukawa N, Rakugi H, Imai M, Kida I, Nagai M, Ohta J, Fukuo K, 
Nabeshima Y, Ogihara T: Upregulation of cAMP is a new functional 
signal pathway of Klotho in endothelial cells.  Biochem Biophys Res 
Commun 2003, 301:424-429.
23. Thomadaki H, Scorilas A: Molecular profile of the BCL2 family of the 
apoptosis related genes in breast cancer cells after treatment with 
cytotoxic/cytostatic drugs.  Connect Tissue Res 2008, 49:261-264.
24. Hengartner MO: The biochemistry of apoptosis.  Nature 2000, 
407:770-776.
25. Gajewski TF, Thompson CB: Apoptosis meets signal transduction: 
elimination of a BAD influence.  Cell 1996, 87:589-592.
26. Zhang K, Kaufman RJ: From endoplasmic-reticulum stress to the 
inflammatory response.  Nature 2008, 454:455-462.
doi: 10.1186/1756-9966-29-99
Cite this article as: Chen et al., Klotho inhibits growth and promotes apop-
tosis in human lung cancer cell line A549 Journal of Experimental & Clinical 
Cancer Research 2010, 29:99